Navigation Links
Fast track to vascular disease
Date:6/3/2011

In Western societies, atherosclerosis of the arteries is one of the leading causes of death. Chronic, localized inflammation of the blood vessel wall facilitates the growth of fibrous plaques, which leads to narrowing or occlusion of the vessel, and thereby promotes heart attacks and stroke. The persistence of the inflammatory reaction is due to a loss of control over the activity of the immune system. So-called dendritic cells are known to play a central role in the adaptive immune response, functioning as activators of other classes of immune cells. Their precise contribution to the pathogenesis of atherosclerosis has, however, been unclear. An international team of researchers led by Professor Christian Weber of Ludwig-Maximilians-Universitt (LMU) Munich and Privatdozentin Alma Zernecke of Wrzburg University has now demonstrated that dendritic cells release the chemokine CCL17 as a signal molecule, which inhibits a feedback mechanism that normally limits the activity of the immune system. This explains why the normally transient inflammatory response is not turned off and becomes chronic. The new study has also identified a potential antidote to the signal molecule. As Professor Weber reports, "We were able to prevent the progression of atherosclerosis using an antibody raised against CCL17." In other words, CCL17 offers a promising starting point for the development of new therapeutic strategies. (Journal of Clinical Investigation, 1 June 2011)

Atherosclerosis can become manifest in various ways. In particular, plaques may suddenly rupture, promoting the formation of a clot that occludes the vessel. If this afflicts the vessels of the heart or brain the result is a heart attack or a stroke. The narrowing of vessels caused by plaque growth can also lead to reduction of the blood supply to the lower limbs and to so-called vascular dementia. Atherosclerosis is initiated by lipid accumulation that occurs directly beneath the inner lining of the blood vessel, and can induce and chronically perpetuate an inflammatory response. Cells of the immune system migrate to the site of the primary lesion and release signaling molecules that attract other types of immune cells which facilitate plaque formation. The atherosclerotic plaques in turn serve as sources of additional signals and mediators, the inflammation reaction gets out of control and continues unchecked, and plaque growth progressively obstructs the flow of blood.

So-called dendritic cells are responsible for determining the targets against which the immune response is directed. They do so by using fragments of target-specific proteins displayed in a molecular complex on their surfaces to activate immune cells called T cells. The T cells have highly variable receptors that enable them to recognize such complexes and to identify the intact target. "Dendritic cells are detectable in arteries and in atherosclerotic tissue, but their precise function in the pathogenesis of plaques has been unclear," explains Weber. "We were particularly interested in learning more about the role of the chemokine CCL17 - a signal protein that is specifically synthesized by mature dendritic cells - in the activation of T cells and in regulating T cell homeostasis."

For their experiments the researchers made use of a transgenic mouse strain in which the gene for CCL17 had been replaced by a DNA sequence encoding the genetic information for the Green Fluorescent Protein (GFP). Thus, in this strain, GFP acts as a proxy for CCL17-producing cells. Since GFP can be visualized by virtue of its fluorescence, the team was able to determine where CCL17-producing cells would normally congregate. This approach also allowed them not only to work out the effects of the lack of CCL17, but also to use advanced methods of microscopy, in particular multiphoton microscopy, to follow how the dendritic cells intrude and accumulate in atherosclerotic plaques and interact with T cells.

In further experiments, the researchers destroyed the T cells of normal mice and replaced them with T cells from the CCL17-deficient mice. Conversely, regulatory T cells were specifically removed from CCL17-deficient mice. "The results of these investigations led us to conclude that CCL17 drives atherosclerosis by inhibiting an important regulatory circuit that acts to restrain the immune response," says Weber. Under normal circumstances, immune reactions are attenuated by regulatory T cells (Tregs) that inhibit other types of immune cells and so ensure that the whole system returns to a balanced state. The new study shows that, in the presence of CCL17, fewer Tregs in the inflamed tissue are activated. In effect, CCL17 disables the Treg-dependent braking mechanism.

"This finding makes CCL17 a promising target for new therapeutic approaches," says Weber, who is anxious to ensure that the results of basic research are transferred as quickly as possible into the clinical setting and find practical medical application. In this case, the first step has already been taken. Using an antibody against CCL17, the authors of the new study were able to block the action of the signal and prevent the progression of atherosclerosis. CCL17 therefore offers a possible handle for new approaches to treatment of the condition. In the next step, Weber and his colleagues hope to clarify the function of the CCL17 receptors on the plasma membrane of the regulatory T cells. (gd)


'/>"/>

Contact: Dr. Christian Weber
kreislaufinstitut@med.uni-muenchen.de
49-895-160-4350
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Related medicine news :

1. Tracking Swine Flu Virus in Pigs Reveals Mutations
2. Studies show Vectra(TM) DA can track early response to rheumatoid arthritis therapy
3. UofL nursing faculty honored for race track clinic success
4. New scientific model tracks form of ovarian cancer to origins in fallopian tube
5. New database to help track quality of medicines in global markets
6. Tracking down the origin of leukemia relapse
7. University of Cincinnati team to track tumor DNA through bloodstream
8. Tet further revealed: Studies track protein relevant to stem cells, cancer
9. IU study: Smoke-free air law had no effect on off-track betting facility business activity
10. New study to use smart phones to track air pollution exposure
11. People Appear to Use Senses to Keep Track of Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: